[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100553930":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":23,"centralContacts":27,"locations":22,"responsibleParty":33,"collaborators":22,"id":36,"slug":37,"hasResults":38,"nctId":39,"briefTitle":40,"officialTitle":40,"acronym":41,"eligibilityCriteria":42,"healthyVolunteers":38,"sex":43,"minAge":44,"maxAge":45,"enrollmentInfo":46,"targetDuration":22,"studyType":49,"phases":50,"briefSummary":52,"conditions":53,"keywords":22,"overallStatus":58,"whyStopped":22,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":22},{"fullName":5,"class":6},"Tata Memorial Centre","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Stratum A (IDH-negative GBM)","EXPERIMENTAL","Adaptive radiotherapy",[13],"Radiation: Adaptive radiotherapy",{"label":15,"type":10,"description":11,"interventionNames":16},"Stratum B (IDH-mutant astrocytoma or oligodendroglioma)",[13],[18],{"type":19,"name":11,"description":20,"armGroupLabels":21,"otherNames":22},"RADIATION","Volumetric and biological adaptive radiotherapy will be delivered based on interval imaging with MRI and PET scan during treatment.",[9,15],null,[24],{"name":25,"affiliation":5,"role":26},"Archya Dasgupta","PRINCIPAL_INVESTIGATOR",[28],{"name":25,"role":29,"phone":30,"phoneExt":31,"email":32},"CONTACT","2224177000","6861\u002F6017","archya1010@gmail.com",{"type":26,"investigatorFullName":34,"investigatorTitle":35,"investigatorAffiliation":5,"oldNameTitle":22,"oldOrganization":22},"Dr Archya Dasgupta","Assistant Professor, Radiation Oncology","100553930","phase-2-glioma-adaptive-radiotherapy-with-development-of-an-artificial-intelligence-workflow-100553930",false,"NCT06492486","Glioma Adaptive Radiotherapy With Development of an Artificial Intelligence Workflow","GLADIATOR","Inclusion Criteria:\n\n* Histological diagnosis of diffuse glioma. Patients with IDH-negative GBM (stratum A) and IDH-mutant glioma (astrocytoma or oligodendroglioma) need radiotherapy (stratum B).\n\nAge: 18-70 years. Karnofsky Performance Scale (KPS) ≥60\n\nExclusion Criteria:\n\n* Multifocal or multicentric disease Not eligible for radical intent radiation. IDH status is unknown or uninterpretable (IHC or gene sequencing). Use of prior radiotherapy to the head-neck region or brain or chemotherapy. Contraindication\u002Funable to undergo MRI or PET scan during radiation.","ALL","18 Years","70 Years",{"count":47,"type":48},60,"ESTIMATED","INTERVENTIONAL",[51],"PHASE2","Gliomas are common primary brain tumors in adults. Gliomas can be classified into different types based on tumor grade, histopathological features, and molecular characteristics. The common types of diffuse gliomas include glioblastoma, astrocytoma, and oligodendroglioma. The standard treatment for diffuse gliomas includes surgery followed by radiation and chemotherapy. As per standard institutional practice, a uniform dose of radiation is delivered to the disease area and MRI is done before and after the treatment. In this study, MRI and PET scan will be done before starting the treatment and standard dose of radiation will be delivered. The interval imaging will be done twice during the course of treatment with MRI and PET, followed by dose modifications. The CT, MRI, and PET will be combined. Based on PET imaging, specific dose will be altered and delivered to specific areas. Dose modification will be done with the help of artificial intelligence. Participant's assessment will be done at regular intervals.\n\nModifications in radiation plans are done based on the changes in disease seen in scans is likely to improve the accuracy of RT treatments. Dose modifications based on imaging to resistant areas will help achieve better tumor control, reduce treatment-related toxicities, precise delivery of the RT and adjusting doses to the organs at risk (OAR) and changes in disease leading to better treatment compliance. Creating an artificial intelligence framework in radiation oncology promises to improve quality of workflow, treatment planning and RT delivery.\n\nThe aim of the study is to develop an artificial intelligence workflow for treatment of glioma with adaptive radiotherapy. This study will be conducted in Tata Memorial Centre on a population of 60 patients for a duration of 2 years. The total study duration is 4 years.",[54,55,56,57],"Diffuse Glioma","Glioblastoma","Adaptive Radiotherapy","Artificial Intelligence","NOT_YET_RECRUITING","2025-09-15",{"date":61,"type":62},"2025-09-16","ACTUAL",{"date":64,"type":48},"2025-11-30",{"date":66,"type":48},"2028-07-30",{"name":5,"class":6}]